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Abstract
Background: Deletions in the long arm of chromosome 11 are observed in a subgroup of advanced stage
neuroblastomas with poor outcome. The deleted region harbours the tumour suppressor gene SDHD that is
frequently mutated in paraganglioma and pheochromocytoma, which are, like neuroblastoma, tumours originating
from the neural crest. In this study, we sought for evidence for involvement of SDHD in neuroblastoma.
Methods: SDHD was investigated on the genome, transcriptome and proteome level using mutation screening,
methylation specific PCR, real-time quantitative PCR based homozygous deletion screening and mRNA
expression profiling, immunoblotting, functional protein analysis and ultrastructural imaging of the mitochondria.
Results: Analysis at the genomic level of 67 tumour samples and 37 cell lines revealed at least 2 bona-fide
mutations in cell lines without allelic loss at 11q23: a 4bp-deletion causing skip of exon 3 resulting in a premature
stop codon in cell line N206, and a Y93C mutation in cell line NMB located in a region affected by germline SDHD
mutations causing hereditary paraganglioma. No evidence for hypermethylation of the SDHD promotor region
was observed, nor could we detect homozygous deletions. Interestingly, SDHD mRNA expression was
significantly reduced in SDHD mutated cell lines and cell lines with 11q allelic loss as compared to both cell lines
without 11q allelic loss and normal foetal neuroblast cells. However, protein analyses and assessment of
mitochondrial morphology presently do not provide clues as to the possible effect of reduced SDHD expression
on the neuroblastoma tumour phenotype.
Conclusions: Our study provides no indications for 2-hit involvement of SDHD in the pathogenesis of
neuroblastoma. Also, although a haplo-insufficient mechanism for SDHD involvement in advanced stage
neuroblastoma could be considered, the present data do not provide consistent evidence for this hypothesis.
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Neuroblastoma (NB) is the most frequent extra-cranial
solid tumour in children, originating from immature neu-
ral crest cells of the sympathetic nervous system [1]. The
tumours show remarkable differences in clinical presenta-
tion ranging from localized to highly metastatic. Although
age and clinical stage are strong prognostic indicators, par-
ticular genetic aberrations, i.e. MYCN amplification and
17q gain, also have a profound predictive power [2,3].
Presently, three major clinico-genetic NB patient sub-
groups have been recognized (subgroup 1, 2A and 2B) [4].
Subgroup 1 consists of NB patients with favourable dis-
ease stage (stage 1, 2 and 4S), most often infants younger
than one year of age presenting with tumours with a near
triploid DNA content and a characteristic pattern of chro-
mosomal instability including the consistent presence of
an extra chromosome 17. The two other NB patient
groups represent mainly older children with high-stage
disease (stage 3 and 4) and poor prognosis. Both NB sub-
groups present with 17q-gain, but are distinguished by
presence of MYCN amplification and 1p-deletion in sub-
group 2B and 11q-deletion often in combination with 3p-
deletion in subgroup 2A [3,5-9].
The first evidence for the occurrence of 11q-deletions in
NB was obtained in 1991 [10]. However, it was not until
recently that a specific patient subgroup with this particu-
lar genetic defect was recognized, representing approxi-
mately 20% of cases [5-9,11-13]. The recurrent finding of
11q-deletions in NB suggests the presence of a tumour
suppressor gene residing on the long arm of chromosome
11. Additional functional evidence for this hypothesis
came from the observation that differentiation of NB cells
can be induced by transfer of an intact chromosome 11
into a NB cell line [14]. Although both comparative
genomic hybridization (CGH) and loss of heterozygosity
(LOH) studies indicate that the majority of the 11q-dele-
tions are distal losses encompassing a large portion of the
long arm [5-9,12,13,15,16], detection of rare small or
interstitial deletions allowed the provisional localization
of an SRO (shortest region of overlap) at 11q23.3 between
markers D11S1340 and D11S1299, encompassing a dis-
tance of approximately 3 Mb [16]. When a single tumour
with two small interstitial deletions is not taken into con-
sideration, the SRO is defined by a small subset of
tumours and spans 18 Mb between markers D11S898 and
D11S1299 (according to UCSC Genome Browser, freeze
version July 2003). This region harbours SDHD, which
encodes the small subunit D (cybS, cytochrome b558) of
the mitochondrial respiratory chain complex II (succi-
nate-ubiquinone oxidoreductase) [17,18] and was
recently recognized as a prototype tumour suppressor
gene [19].
The first evidence for a role of SDHD in tumour develop-
ment was obtained by the discovery of germline muta-
tions in this gene as the cause for familial paraganglioma
(PGL) [19]. Somatic and occult germline SDHD muta-
tions were also detected in patients with apparently spo-
radic pheochromocytoma (PC) [20,21]. It seems that
most of the individuals with PC possess SDHD mutations
in the 5' portion of the gene causing complete disassem-
bly of complex II, whereas PGL are associated with muta-
tions in the 3' region of the gene causing partial
inactivation of its catalytic activity [19-28]. PGL and PC
are histologically related to NB as they are all neural crest
derived. NBs consist of immature neuroblasts, whereas
PGL and PC contain mature chromaffin cells. Of further
interest is the fact that, in addition to the well established
role of SDHD in oxidative phosphorylation, SDHD has
also been presumed to contribute to the function of the
mitochondria as oxygen sensors. It was shown that SDHD
inactivation leads to a pseudo-hypoxic state and upregula-
tion of hypoxia responsive genes, possibly through
increased production of reactive oxygen species (ROS)
[23]. A hypoxia-induced shift toward a neural crest-like
phenotype has been shown to result in more aggressive
NB cells with increased potential to metastasize [29].
Consequently, inactivating SDHD mutations or reduced
activity of SDHD might lead to impaired oxidative phos-
phorylation and hypoxia and thus contribute to NB
oncogenesis.
In view of the above, we considered SDHD as a positional
and functional candidate for the presumed NB tumour
suppressor gene on 11q23. In order to search for evidence
for involvement of SDHD in NB development, an exten-
sive series of investigations was performed on the DNA,
RNA and protein level.
Methods
NB patient and cell line samples
Neuroblastoma (NB) tumour samples (at least 70%
tumour cells) were collected at the Ghent University Hos-
pital (Ghent, Belgium) (n = 32) and in the Molecular
Oncology Unit (Lyon, France) (n = 35). Ethical approval
was obtained for the collection of the tumour samples.
The latter group includes selected patients with stage 3 or
4 NB without MYCN amplification. For all NB patients
constitutional leukocyte DNA was available. In addition,
31 NB cell lines were included in the analysis of which
karyotypes were available. For 20 of these cell lines, com-
parative genomic hybridization (CGH) data and/or M-
FISH (multicolour fluorescence in situ hybridization)
results have been published [30-32]. For screening of
sequence variants in a normal population, leukocyte DNA
from 135 unrelated healthy individuals was used. DNA
was extracted as previously described [33].Page 2 of 15
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SK-N-FI, CLB-GA, LA-N-2 and NGP were treated with
puromycine (100 µg/ml) during 6 hours in order to pre-
vent possible nonsense mediated RNA decay of variant
SDHD transcripts. RNA of the cell line pellets (treated and
untreated) was extracted with the RNeasy Mini kit (Qia-
gen) according to the manufacturer, followed by RNase
free DNase treatment on column (Qiagen). A fraction of
the untreated NB cell line cultures was also used for func-
tional enzyme assays.
11q23 status of samples
Determination of the 11q23 status in NB cell lines and tumours with 
LOH or FISH
The 11q status of the cell lines was evaluated using FISH.
FISH was performed using the LSI MLL (11q23.3) Spec-
trumOrange probe (Vysis) and BAC clone RP11-93E4 for
the CRTAM gene (11q24.1) in combination with a centro-
meric probe for chromosome 11. Labelling and FISH was
performed as described [34]. For each case at least twenty
metaphase chromosomes and 100 interphase nuclei were
screened.
All NB patients were analyzed with 4 microsatellite mark-
ers on 11q23: D11S1986 (11q23.1), D11S1998
(11q23.3), D11S1356 (11q23.3) and D11S1299
(11q23.3), of which D11S1986 and D11S1998 are imme-
diately flanking the SDHD gene. In order to discriminate
between whole chromosome loss, and unbalanced 11q
loss (= partial 11q loss), two microsatellite markers on
11p (D11S922 on 11p15.5 and D11S1324 on 11p14.1)
were analyzed in patients that showed allelic imbalance
for all 11q markers (positions of the markers are accord-
ing to the UCSC Genome Browser, freeze version July
2003). Scoring of loss of heterozygosity (LOH) was per-
formed by calculation of the allelic imbalance factor (AIF)
[35], whereby AIF > 2 denotes allelic imbalance, and AIF
> 5 denotes LOH. Experimental conditions for the fluores-
cent based LOH screening can be obtained from the
authors upon request.
Homozygous deletion screening in NB cell lines
Real-time quantitative PCR primers were designed in the
four exons of SDHD using Primer Express v2.0 (Applied
Biosystems) (Table 1). Exon 1 was too small for primer
design in the exonic region; therefore primers flanking the
exonic region were designed. Real-time quantitative PCR
and quantification was performed as described [33].
MSP
On the 31 NB cell lines and on another series of 50 NB
tumours of which 15 were included in the mutation anal-
ysis, methylation-specific PCR (MSP) was performed as
described, with minor modifications [36]. MSP primers
were designed using the web-based MSP design software
MethPrimer http://www.urogene.org/methprimer/[37]
and checked for specificity using the methBLAST software
http://medgen.ugent.be/methblast/ (Pattyn et al., in prep-
aration). Primers were designed in a CpG island close to
the start of the gene (putative SDHD promotor) (chr11:
111495002–111495330: UCSC Genome Browser freeze
version July 2003) (methylated forward
5'GTAGTCGGGATCGAGTATTAGTGAGTC3', methylated
reverse 5'AATAAACCGAAAATCGAAAAACGAT3',
unmethylated forward
5'AGTTGGGATTGAGTATTAGTGAGTTGT3', unmethyl-
ated reverse
5'ACTAAATAAACCAAAAATCAAAAAACAAT3'). Amplifi-
cation mixtures (50 µl) for the PCR reaction contained 50
ng template DNA, 1× Platinum Taq PCR reaction buffer
(Invitrogen), 6 mM MgCl2, 200 µM of each dNTP, 1.25 U
Platinum Taq polymerase (Invitrogen), 3% DMSO and
300 nM of each primer. The cycling conditions comprised
4 min polymerase activation at 93°C, 40 cycles with dena-
turation at 93°C for 30 sec, annealing at 64°C (methyl-
ated primers) or 65°C (unmethylated primers) for 30 sec
and extension at 72°C for 30 sec, and a final extension for
5 min at 72°C. SssI methylase (New England Biolabs)
treated DNA, following the manufacturer's instructions
and normal human genomic DNA were used as a positive
and negative control respectively after bisulfite
modification.
Mutation analysis
DHPLC analysis
Intronic primers flanking the SDHD exons were designed
using Primer Express v2.0 (Applied Biosystems), based on
the publicly available SDHD genomic sequence (acces-
sion number AB026906) (Table 2). PCR reactions were
performed on a PTC-200 DNA engine (MJ Research).
Amplification mixtures (25 µl) contained 10 ng template
DNA, 1× Platinum Taq PCR reaction buffer (Invitrogen),
2.5 mM MgCl2, 200 µM of each dNTP, 1 U Platinum Taq
polymerase (Invitrogen) and 500 nM of each primer. The
cycling conditions comprised 3 min polymerase activa-
tion at 94°C, 35 cycles with denaturation at 92°C for 20
sec, annealing at 60°C for 20 sec and extension at 72°C
for 2 min, a final extension for 5 min at 72°C and a slow
decrease in temperature to 25°C over 30 minutes. One µl
of the PCR products was analyzed on a Ready-To-Run
Agarose Gel (1.2%) (Amersham Biosciences).
Denaturing high-pressure liquid chromatography
(DHPLC) was performed using the Wave system (Transg-
enomic). The melting profile of each fragment was deter-
mined using the Wavemaker software v4.1
(Transgenomic). Crude PCR product was injected into a
preheated, fully equilibrated chromatographic column for
the DHPLC analysis. Exon 1 fragments were eluted at a
temperature of Tm(= 62.1°C)+0.7°C and Tm+1.5°C. ExonPage 3 of 15
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55.7°C)+4.8°C. Exon 3 fragments were eluted at a tem-
perature of Tm(= 57.4°C)-0.4°C, Tm+1.1°C and
Tm+3.8°C. Exon 4 fragments were eluted at a temperature
of Tm(= 56.4°C)-0.4°C, Tm+1.6°C and Tm+3.2°C. Elution
of the fragments was performed using standard condi-
tions according to the manufacturer. Elution profiles were
analyzed using the Wavemaker software.
Sequencing
Sequencing was performed on all cell lines and on tumour
samples with aberrant DHPLC elution peaks (except from
the noncoding region of exon 4 that was sequenced in all
NB cell lines without preceding DHPLC mutation
screening).
Amplified fragments were purified using the Montage
PCR96 filter plates (Millipore) or by excision of the frag-
ment of interest from a 1.5% TBE-agarose gel and purifi-
cation on a GenElute Minus EtBr Spin Column (Sigma-
Aldrich). Cycle sequencing was performed using purified
amplicons (3–10 ng), the above-mentioned primers
(Table 2) at a concentration of 80 nM and the ABI PRISM
BigDye Terminators v3.0 Cycle Sequencing Kit (Applied
Biosystems), with the following thermocycling condi-
tions: 25 cycles at 92°C for 10 sec, 55°C for 5 sec and
60°C for 3.5 min. The products were run on an auto-
mated sequencer ABI3100 (Applied Biosystems) after iso-
propanol precipitation. Sequence analysis was performed
with the SeqScape v1.1 software (Applied Biosystems).
Allelic discrimination screening for 2 sequence variants using MGB 
probes
PCR primers and minor groove binder (MGB) probes for
sequence variant IVS4-32T>C were designed using Primer
Express v2.0 following the user bulletin guidelines for the
design of MGB probes (Applied Biosystems): forward
primer 5'TTTTTTGCAGCCAAGTTATCTGTATAG3',
reverse primer 5'TGTCCAAGGCCCCTAAAGAA3', MGB
probe allele 1 5'TGTGGTTTTTtATTGATG3' labelled with
6-FAM and MGB probe allele 2
5'TGTGGTTTTTcATTGAT3' labelled with VIC. To address
the frequency of the sequence variant g.7876A>G (Y93C)
in a normal population, the following primers and probe
were designed: forward primer
5'GGCTGCTTATTTGAATCCTTGCT3', reverse primer
5'ACTTGCCAGTGACCATGAAGAGT3' and MGB probe
variant allele 5'ATGGACTgTTCCCTG3' labelled with VIC.
The reaction mixture contained 10 ng of DNA, 100 nM of
each MGB probe, 300 nM of each primer and 1× qPCR
Mastermix (Eurogentec). For the screening of the
g.7876A>G variant, multiplex PCR was performed using
primers and probe of the normal allele of the above-men-
tioned SNP (IVS4-32T>C) and primers and probe for the
variant allele g.7876A>G. Reactions were performed on
the iCycler Thermal Cycler (Bio-Rad) with the following
thermocycling conditions: an initial activation step at
95°C for 10 min, 50 cycles of 95°C for 15 sec and 60°C
for 1 min. Allelic discrimination data analysis was per-
formed on the iCycler IQ Optical System Software v3.0a
(Bio-Rad).
Table 1: Primer sequences used for homozygous exon deletion screening with real-time quantitative PCR
amplicon forward reverse
SDHD exon 1 5'AGGAACGAGATGGCGGTTCT3' 5'TCCTAGGGCACCGCAAAC3'
SDHD exon 2 5'CCAGTGGTCAGACCTGCTCAT3' 5'TGCTGCACTCCACACCATTC3'
SDHD exon 3 5'GACTAGCGAGAGGGTTGTCAGTGT3' 5'CATCGCAGAGCAAGGATTCA3'
SDHD exon 4 5'TGGCACTTTCAGCTTTAACCTTT3' 5'CACAGCATGGCAACAGCTTT3'
Table 2: Primer sequences used for denaturing high performance liquid chromatography (DHPLC) and sequencing
amplicon forward reverse
SDHD exon 1 5'GCACCGCCTCTCGACTTC3' 5'TGCTGTGATTTCGGTATTTTCTTC3'
SDHD exon 2 5'AACCCCAGTGAAATAGATGCTATCTTC3' 5'AGTCCTGCTAAAGGCATGACCATTA3'
SDHD exon 3 5'CACTGCCTGTCAGTTTGGGTTAC3' 5'GGGCATTTCAATCAACTTCTCCC3'
SDHD exon 4 5'TCCCCTAAAGAAGCAAACAGTGAC3' 5'GAGCTTAATGGCATGACAAAGCAG3'
SDHD exon 4 Noncoding 
region (only for sequencing)
5'GTGGTTTTTTATTGATGTTATGATTTT3' 5'AATCTCAATTTACAGTTGGTAGTATTTT3'Page 4 of 15
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Full-length SDHD mRNA amplification
In order to investigate predicted or putative splice variants
caused by the 4 bp-deletion in NB cell line N206 and
SDHD sequence variants present in other cell lines, the
coding region of the full-length SDHD mRNA was ampli-
fied for cell lines N206, SK-N-AS, SK-N-SH, NMB, SK-N-
FI, CLB-GA, LA-N-2 and NGP, before and after puromycin
treatment. RNA extraction, DNase treatment and cDNA
synthesis were performed as described [38]. Subsequent
PCR was performed with forward primer
5'AGGAACGAGATGGCGGTTCTC3' (exon 1) and reverse
primer 5'GCTTCCACAGCATGGCAACA3' (exon 4). PCR
products were run on an agarose gel, purified and
sequenced using the above-mentioned protocol. The
sequence information also provided evidence on the
allelic mRNA expression status of SDHD.
Quantification of SDHD expression using real-time 
quantitative RT-PCR
Relative SDHD expression levels were determined using
an optimized two-step SYBR Green I RT-PCR assay [38]
with minor modifications in 31 cell lines, 7 normal con-
trol samples (human brain, trachea, lung, heart, breast,
kidney, liver) and in laser capture microdissected foetal
neuroblast cells [39]. The comparative CT method was
used for quantification. PCR reagents were obtained from
Eurogentec as SYBR Green I mastermixes and used accord-
ing to the manufacturer's instructions. Primers in exon 3
were designed using Primer Express (see Primers Exon 3 in
Table 1). Reactions were run on an ABI5700 (Applied Bio-
systems). Gene expression levels were normalized using
the geometric mean of the 4 most stable internal control
genes in NB (i.e. UBC, HPRT1, SDHA and GAPD) as
reported previously [40].
Complex II activity and protein assays
Enzyme activities were determined spectrophotometri-
cally as previously described [41].
Protein amount was determined with immunoblot analy-
sis of complex II Fp fragment as previously described [42].
Relative protein amounts of complex II compared to com-
plex IV were measured using the TotalLab software (Amer-
sham Biosciences).
Ultrastructural analysis of mitochondria in NB cell lines
Mitochondria of NB cell lines LA-N-2, SK-N-AS, CLB-GA,
NGP, CHP-901, SK-N-SH, SK-N-FI, N206, SJNB-12, SJNB-
8, NMB, SJNB-10 and IMR-32, breast carcinoma cell line
MCF-7 and, Ewing sarcoma cell line SK-N-MC were ana-
lysed by electron microscopy. Monolayers from these cell
lines were briefly rinsed twice in PBS and then immersed
at room temperature in 3 % glutaraldehyde buffered with
Na-cacodylate at pH 7.3 for 1 h. After rinses in this buffer
with 1 % bovine serum albumin, cells were scraped off
with a rubber policeman, and centrifuged with 3 % glutar-
aldehyde. After washing, the pellets were postfixed in 2 %
buffered OsO4 for 1 h at 4°C. Block staining in uranylac-
etate (UAc) in 70 % ethanol was followed by dehydration
in ethanol and propylene oxide, and embedding in Epon.
Ultrathin sections were counterstained with UAc and lead.
At least 2 cells in each culture were photographed at a
magnification of 20,000 in a Zeiss electron microscope
operating at 50 KV. Per culture, 25–63 mitochondria were
examined. Their projected length (largest straight dis-
tance) was measured and matrix electron density was
compared to the surrounding cytosol.
Electron microscopic files were made on 11 archived neu-
roblastic tumours. In addition, previously published cases
were examined for mitochondria morphology.
Results
SDHD deletion, mutation and methylation analysis
11q23-deletion screening
Previous karyotyping, comparative genomic hybridiza-
tion (CGH) and/or M-FISH revealed 11q-deletions in 9
out of 31 neuroblastoma (NB) cell lines (CLB-GA, GI-ME-
N, IMR-32, LA-N-6, NBL-S, NGP, SK-N-AS, NMB, N206)
[30-32]. In this study, the presence of 11q23-deletions
was confirmed by FISH in all these cell lines except N206
for which the deletion was located distal to the MLL locus
(11q23.23) (not shown) (Table 3). Sequencing analysis
of SDHD on 11q23 demonstrated that the allelic imbal-
ance in NMB does not cause loss of heterozygosity (see
later). No previously unnoticed submicroscopic 11q23-
deletions were detected. Screening for homozygous dele-
tions in all SDHD exons was negative for the 31 NB cell
lines.
In 20 of the 67 NB tumour samples, loss of heterozygosity
(LOH) or allelic imbalance (AI) (AIF > 2) in the 11q23
region was found (Table 3): unbalanced 11q LOH (i.e.
partial allelic loss of the long arm of chromosome 11) in
2/32 patients of the Ghent University Hospital (Ghent,
Belgium) and in 7/35 patients of the Molecular Oncology
Unit (Lyon, France) and loss of markers on both chromo-
some arms (indicating whole chromosome 11 loss, or co-
occurrence of 11q and 11p allelic loss) in 3/32 patients of
the Ghent University Hospital and 8/35 patients of the
Molecular Oncology Unit (Table 3). The higher frequency
of chromosome 11 LOH in the patient subgroup of the
Molecular Oncology Unit can be explained by the
selection for patient samples of high stage without MYCN
amplification, in contrast to the other patient subgroup
for which samples were unselected.Page 5 of 15
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BMC Cancer 2004, 4:55 http://www.biomedcentral.com/1471-2407/4/55Table 3: (A) 11q23 LOH data of NB patients (35 patients form the Molecular Oncology Unit (Lyon, France) (F-samples) and 32 patients 
from the Ghent University Hospital (Ghent, Belgium) (G-samples)). Based on the allelic imbalance factor (AIF) of 6 markers (4 on 11q23 
and 2 on 11p) normal 11q23 status was distinguished from unbalanced 11q LOH and loss of both 11q and 11p (here indicated as whole 
chromosome loss) (- = no data available) and (B) 11q23 status in NB cell lines based on FISH, LOH, karyotypes, CGH and/or M-FISH
A
NB tumour 
case
11q23 LOH 
status
MYCN ampl 1p del stage NB tumour 
case
11q23 LOH 
status
MYCN 
ampl
1p del stage
F1 normal no no 3 G1 normal no no 4
F2 normal no no 3 G2 whole chr11 loss no no 4
F3 normal no no 3 G3 normal no no 1
F4 normal no no 4 G4 normal no no 1
F5 whole chr11 loss no no 4 G5 normal no no 2
F6 unb [11q]LOH no no 4 G6 normal - no 3
F7 normal no no 4 G7 normal - - 4
F8 normal no no 3 G8 normal no no 1
F9 normal no no 4 G9 whole chr11 loss no no 4
F10 whole chr11 loss no no 3 G10 normal no no 4
F11 normal no no 4 G11 normal no no 1
F12 normal no no 4 G12 normal no no 4
F13 normal no no 3 G13 normal no yes 1
F14 whole chr11 loss no no 3 G14 whole chr11 loss no no 3
F15 whole chr11 loss no yes 4 G15 normal no no 3
F16 normal no no 3 G16 normal - no 4
F17 unb [11q]LOH no no 4 G17 normal no no 3
F18 unb [11q]LOH no yes 4 G18 normal no yes 1
F19 normal no no 4 G19 normal no no 4S
F20 normal no no 3 G20 normal yes yes 3
F21 unb [11q]LOH no no 4 G21 unb [11q]LOH no no 3
F22 whole chr11 loss no no 3 G22 unb [11q]LOH yes yes 4
F23 normal no no 3 G23 normal no no 4
F24 normal no no 3 G24 normal yes yes 4
F25 whole chr11 loss no no 3 G25 normal no no 4
F26 unb [11q]LOH no no 4 G26 normal no yes 4
F27 whole chr11 loss no no 3 G27 normal no no 3
F28 normal no no 3 G28 normal - no 2
F29 unb [11q]LOH no no 4 G29 normal no no 3
F30 normal no yes 4 G30 normal no no 1
F31 normal no no 4 G31 normal - no 3
F32 normal no no 4 G32 normal no no 4S
F33 whole chr11 loss no no 3
F34 normal no yes 4
F35 unb [11q]LOH no no 4
B
NB cell line 11q23 status MYCN ampl 1p del
CHP-134 normal yes yes
CHP-901 normal yes yes
CHP-902R normal yes yes
CLB-GA deletion no no
GI-M-EN deletion no yes
IMR-32 deletion yes yes
LA-N-1 normal yes yes
LA-N-2 normal yes no
LA-N-5 normal yes yes
LA-N-6 deletion no yes
N206 normal yes yes
NBL-S deletion no no
NGP deletion yes yes
NLF normal yes yes
NMB normal yes yes
SJNB-12 normal no yes
SJNB-1 normal no yes
SJNB-10 normal yes yesPage 6 of 15
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Denaturing high performance liquid chromatography
(DHPLC) analysis and subsequent sequencing of the
SDHD gene in 31 NB cell lines and 67 NB tumour samples
revealed the presence of sequence variants in 5 NB cell
lines and 4 NB tumour samples (Table 4).
Two variants were considered as bona fide mutations (Fig-
ure 1). The first, a Y93C missense mutation in cell line
NMB, was not detected in 135 unrelated healthy individ-
uals. The second variant detected in NB cell line N206,
represented a 4 bp deletion on the exon-intron boundary
causing an exon 3 skip leading to a premature stop codon.
Interestingly, both effects are located within regions that
are frequently affected in paraganglioma (PGL). Unfortu-
nately no normal or primary tumour material of the
patients from which the N206 and NMB cell lines were
derived was available to test whether these are germline or
somatic mutations.
In one patient without 11q allelic loss (F11) we observed
in both tumour and constitutional DNA a TCTA insertion
at position IVS2+37. However, no additional tumour
material nor parental material was available for further
analysis. So, it remains unclear whether this is a true
mutation or a rare polymorphism.
In addition, 1 new and 4 known polymorphisms were
observed. The H50R variant found in cell line LA-N-2 was
described as a polymorphism in several studies [43-45].
This is also true for the G12S change found in tumour and
constitutional DNA of patient F18 [21]. The previously
reported polymorphisms IVS3-29A>G [25] and S68S
[25,27,28,44,46,47] were detected in cell lines NGP, NMB
and SK-N-FI, in both tumour and constitutional DNA of
patients F18 and F35, and in constitutional DNA of
patient F22. In all cases, these last two polymorphism
(IVS3-29A>G and S68S) were present together with the
IVS4-32T>C variant, previously described by Taschner
and colleagues [28]. Allelic discrimination screening in
135 unrelated individuals revealed an incidence of the
IVS4-32T>C polymorphism of 4.4% (= 6/135; allele
frequency 2.2%). This is similar to the incidence found in
NB cell lines (3/31 = 9.7%) and NB patient constitutional
DNA (3/67 = 4.5%, allele frequency = 2.2%).
The presence of the IVS3-29A>G, S68S and IVS4-32T>C
variants in a cell line (NGP) and two tumours (F18 and
F35), in which one of both SDHD alleles has been
deleted, indicates that all three variants are located on the
same allele, representing a low frequent haplotype.
MSP analysis
SDHD promotor hypermethylation was tested for 31 NB
cell lines and 50 NB patients using methylation-specific
PCR (MSP). No evidence for methylation was obtained in
any of the analyzed NB cases.
Analysis of the 4 bp deletion in the cell line N-206
Amplification of the full-length SDHD cDNA showed that
a 4 bp deletion in the intron-exon boundary in cell line
N206 caused skipping of exon 3 leading to a premature
stop codon.
No alternative transcripts could be detected in cell lines
NMB, SK-N-FI, NGP and LA-N-2 carrying basepair vari-
ants (and 3 control cell lines without sequence variants
SK-N-SH, SK-N-AS and CLB-GA) when grown with or
without puromycin (Figure 1).
The above-mentioned cDNA transcript sequencing
revealed that SDHD is bi-allelically expressed, thus
supporting recent observations in lymphoblastoid cell
lines, adult kidney and adult and fetal brain [19,22], but
in contrast with the initially reported paternal mono-
allelic expression in PGL tissue [22].
SJNB-6 normal yes yes
SJNB-8 normal yes yes
SK-N-AS deletion no yes
SK-N-BE normal yes yes
SK-N-FI normal no no
SK-N-SH normal no no
SMS-KAN normal yes yes
SMS-KCNR normal yes yes
STA-NB-10 normal yes yes
STA-NB-3 normal yes yes
STA-NB-8 normal yes yes
TR-14 normal yes yes
UHG-NP normal yes yes
Table 3: (A) 11q23 LOH data of NB patients (35 patients form the Molecular Oncology Unit (Lyon, France) (F-samples) and 32 patients 
from the Ghent University Hospital (Ghent, Belgium) (G-samples)). Based on the allelic imbalance factor (AIF) of 6 markers (4 on 11q23 
and 2 on 11p) normal 11q23 status was distinguished from unbalanced 11q LOH and loss of both 11q and 11p (here indicated as whole 
chromosome loss) (- = no data available) and (B) 11q23 status in NB cell lines based on FISH, LOH, karyotypes, CGH and/or M-FISH Page 7 of 15
(page number not for citation purposes)
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SDHD expression levels were measured using real-time quantitative
PCR in 31 NB cell lines, normal foetal neuroblast cells (16, 18 and
19 weeks gestational time) and 7 normal adult tissues (brain, heart,
kidney, liver, lung, trachea and breast) (Figure 2). The SDHD mRNA
level was significantly lower in NB cell lines compared to both nor-
mal neuroblast cells (Mann-Whitney test: P = 5.31E-06) and normal
adult tissue mRNA samples (Mann-Whitney test: P = 1.49E-05).
SDHD mRNA levels were significantly reduced in cell lines with 11q
allelic loss and SDHD mutated cell lines (i.e. NMB and N206) (N =
9) compared to cell lines without 11q allelic loss (N = 22) (Mann-
Whitney test: P = 1.49E-03).
SDHD functional analysis
As the SDHD gene encodes the small subunit D of the mitochon-
drial respiratory chain complex II we decided to assess the effect of
the basepair variants on the activity of complex II of the respiratory
chain by spectrophotometrical measurements in 5 NB cell lines
(N206, NMB, SK-N-FI, NGP and LA-N-2) and 3 control NB cell lines
without sequence variants (SK-N-SH, SK-N-AS and CLB-GA). No
significant differences in complex II enzyme activity could be dem-
onstrated. Although, in LA-N-2 a slight decrease of complex II activ-
ity was observed (data not shown).
On above-mentioned cell lines and NB cell lines CHP-901, SJNB-
12, SJNB-8, SJNB-10 and IMR-32, breast cancer cell line MCF7 and
Ewing sarcoma cell line SK-N-MC, immunoblotting of the Fp frag-
ment of complex II showed no significant variation in abundance
among the tumour cell lines (data not shown).
Table 4: SDHD base pair variants found in NB tumour samples and cell lines, the position of the variant, the change in the protein caused by the variant and 
the conclusion (mutation or polymorphism); also listed for each tumour and cell line are the genomic status for chromosome arm 11q (n.d. = not done) (for 
cell lines: chromosome 11 centromere copy number versus 11q23 copy number according to FISH, for tumours: normal, unbalanced LOH (unb [11q]LOH) 
or whole chromosome 11 loss according to microsatellite marker analysis), MYCN status (normal or amplified), 1p status and tumour stage when available 
(- = not available).
NB tumour 
case 
number / 
NB cell line
11q23 status 
by 
microsatellit
e marker 
analysis
11q23 status by 
FISH
SDHD base pair 
variant
exon change in 
protein
mutation (M) 
or 
polymorphism 
(P)
variant present 
in 
constitutional 
(C)/ tumour (T)
MYCN 1p del stage
F11 normal n.d. g.6911ins(TCTA) IVS2+37ins(TCTA) ? (see text) ? (see text) C+T normal no 4
F18 unb [11q] 
LOH
n.d. g.5842 G>A 1 G12S P C+T normal yes 4
g.7750 A>G IVS3-29 A>G P C+T
g.7802 C>T 3 S68S P C+T
g.13678 T>C IVS4-32 T>C P C+T
F22 whole chr11 
loss
n.d. g.7750 A>G IVS3-29 A>G P C normal no 3
g.7802 C>T 3 S68S P C
g.13678 T>C IVS4-32 T>C P C
F35 unb [11q] 
LOH
n.d. g.7750 A>G IVS3-29 A>G P C+T
g.7802 C>T 3 S68S P C+T
g.13678 T>C IVS4-32 T>C P C+T
LA-N-2 n.d. 2/2 
heterozygous
g.6854 A>G 2 H50R P - amplified no 4
N206 n.d. 2/2 
heterozygous
g.79124del(GGCA) 3 exon 3 skip, 
premature 
stop codon
M - amplified yes 4
NGP n.d. 2/1 
hemizygous
g.7750 A>G IVS3-29 A>G P - amplified yes -
g.7802 C>T 3 S68S P
g.13678 T>C IVS4-32 T>C P
NMB n.d. 4/3 allelic 
imbalance/ 
heterozygous 
(based on 
sequence)
g.7750 A>G IVS3-29 A>G P - amplified yes 4
g.7802 C>T 3 S68S P
g.7876 A>G 3 Y93C M
g.13678 T>C IVS4-32 T>C P
SK-N-FI n.d. 2/2 
heterozygous
g.7750 A>G IVS3-29 A>G P - no no -
g.7802 C>T 3 S68S P
g.13678 T>C IVS4-32 T>C PPage 8 of 15
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Details of sequencing profiles: (A) Deletion of GGCA in cell line N206 causing skip of exon 3 and (B) Y93C mutation in cell line 
NMB; (C) RT-PCR (reverse transcriptase PCR) on cell lines grown with or without puromycine (T = treated, U = untreated) 
revealed a transcript variant in cell line N206, caused by the GGCA deletion (lane 1 and 2).Page 9 of 15
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lines
Electron microscopic analysis of NB cell lines revealed
that the morphology of the mitochondria is heterogene-
ous between the different cell lines, with respect to length,
dilated intracrista spaces and condensation of the matrix
(Table 5 and Figure 3). In most of the cell lines the elec-
tron dense matrix granules are absent. A striking observa-
tion are dilations of the mitochondrial intracrista spaces
in most of the NB cell lines including N206 (Figure 3A),
but not NMB (Figure 3B). Cell line LA-N-2 shows very
large mitochondria (Figure 3D). However, these
observations are not the same as described for PGL, where
swollen mitochondria are seen with an empty matrix and
short or absent cristae [48].
In order to examine whether dilated mitochondrial cristae
are a feature of many, or all NBs, we studied the
mitochondria in electron micrographs from 11 archived
and 22 previously published neuroblastic tumours [49-
53]. Dilated cristae were seen in 11 tumours but they were
limited to a minority of the mitochondria (2–23%), in
contrast to several of the cell lines of which most mito-
chondria are altered. In several of the analyzed NB
tumours, partially vacuolated matrices were occasionally
observed.
Discussion
In this study, we investigated the possible involvement of
SDHD in neuroblastoma (NB) tumourigenesis. In a first
step, mutation and methylation analyses were performed
on a large panel of NB cell lines and tumours. A total of
seven sequence variants (in nine different samples) were
detected of which two could represent bona fide
mutations, i.e. missense mutation Y93C in cell line NMB
and a 4 bp deletion in cell line N206.
SDHD mRNA levels in NB cell lines (light gray), neuroblast cells (gray) and human normal control samples (white)Figure 2
SDHD mRNA levels in NB cell lines (light gray), neuroblast cells (gray) and human normal control samples (white). Significantly 
reduced SDHD mRNA expression levels in NB cell lines with 11q23 allelic loss compared to 11q23 intact NB cell lines (P = 
5.31E-06) and normal tissue samples (P = 1.49E-05).Page 10 of 15
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ously and screening of 135 unrelated healthy individuals
for this variant was negative. The substituted amino-acid
is located within a region of the SDHD protein frequently
altered due to germline mutations in paraganglioma
(PGL) families (loss of Y93 [22] and two missense muta-
tions, i.e. D92Y [19,28,46] and L95P [28]). These residues
are part of the third transmembrane helix of the SDHD
protein [54].
The second mutation has not been reported either. This
mutation results from a 4 bp deletion in the 3' exon-
intron boundary of exon 3 resulting in skipping of exon 3
leading to a transcript with a premature stop codon. The
predicted truncated protein has another carboxyterminal
amino-acid sequence from H56 on and its normal
function is assumed to be impaired as carboxyterminal
amino-acids involved in ubiquinone and heme b binding
are missing (H71, D82 and Y83) and consequently the
structure of the transmembrane subunit and/or associa-
tion of the catalytic domain subunits SDHA and SDHB to
the membrane would be disrupted [54].
The functional consequence of one sequence variant
located within an intronic sequence (IVS2+37ins(TCTA))
is more difficult to evaluate due to lack of fresh tumour
material, and parental DNA. Further analysis is needed in
order to reveal a possible effect on splicing or RNA
stability.
Table 5: Ultrastructural analysis of mitochondria
dilation of 
cristae*
density of 
matrix°
configuration# matrix 
granules°°
mean projected
length (µm)
max projected
length (µm)
CHP-901 + -+ + + 0,65 1,31
CLB-GA ++ + + 0,69 1,92
IMR-32 + + + - 0,69 1,27
LA-N-2 ++ + - 0,82 2,18
MCF-7 - + + - 1,06 3,11
N-206 +++ + - 0,84 1,65
NGP +++ + - 0,84 1,74
NMB - - + - 0,68 1,26
SJNB-10 +++ + - 0,63 1,69
SJNB-12 + + - 0,47 1,23
SJNB-8 - -+ + - 1,02 3,40
SK-N-AS ++ + - 0,66 1,47
SK-N-FI + - + - 0,65 1,32
SK-N-MC - - + - 0,90 2,03
SK-N-SH + -+ + + 0,56 1,31
*: +cristae of some mitochondria dilated; ++cristae of many mitochondria dilated; +++all mitochondria have dilated cristae;
°: +matrix of most mitochondria is more electron dense than the cytosol; -+part of the mitochondria are dense, but others have a light matrix; -
mitochondrial matrix is lighter than or equal to cytosol;
#: +mitochondria with an orthodox configuration are present; in the same cell or culture other mitochondria may have dilated cristae and a dense 
matrix;
°°: -few or no matrix granules; +matrix granules visible in many or most mitochondria, normal image;Page 11 of 15
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detected in 5 NB cell lines and 3 tumour samples. Addi-
tional screening for homozygous deletions in all cell lines
and methylation in cell lines and tumours were negative.
Based upon these results, we can exclude a role for SDHD
as a classical tumour suppressor gene in NB. However, the
finding of two apparently bona fide SDHD mutations in
NB without allelic loss of distal 11q leaves the possibility
open that the gene contributes to NB oncogenesis due to
haplo-insufficiency, rather than functional inactivation of
both alleles. In order to investigate this possibility, we
decided to perform further studies at transcript and pro-
tein level. Interestingly, SDHD expression was shown to
be consistently lower in cell lines with 11q allelic loss ver-
sus NB cell lines without loss and also significantly
decreased in NB cell lines as compared to normal foetal
adrenal neuroblast cells of 16, 18 and 19 weeks gesta-
tional time with a mean fold difference of 3.61 between
neuroblast cells and NB cell lines. A similar correlation
between 11q LOH and reduced SDHD expression was
recently described in colorectal and gastric cancer [55].
Our findings at mRNA transcript level, however, did not
match with results obtained from further analysis at pro-
tein level. Complex II activity and quantitative protein
analysis revealed no significant difference between cell
lines with or without 11q allelic loss or SDHD mutation.
However, measurement of complex II activity might only
reflect part of the functional properties of SDHD. Also,
measurement of differences in protein quantity is far less
sensitive than Q-PCR at transcript levels. Therefore, these
observations at present do not fully exclude SDHD
involvement in NB. Finally, we also looked at the mor-
phologic characteristics of the mitochondria as a possible
clue to SDHD dysfunction. In keeping with, at best, partial
loss of function of SDHD, we did not observe similar gross
morphologic changes as reported for PGL with SDHD
mutations (swelling with loss of matrix density and gen-
eralized rarefaction of cristae), the latter being character-
ized by destabilization of complex II with loss of
enzymatic activity [48]. However, most of the cell lines
showed dilated mitochondrial cristae. It has been demon-
strated that this is a reversible phenomenon, and parallels
arise in intracellular ADP/ATP ratio or low energy state
[56]. Subsequent combined ultrastructural and biochem-
ical studies from several authors indicated that dilation of
cristae follows a decrease in mitochondrial membrane
potential that can be provoked by various experimental
procedures [57,58]. This configuration was detected in
only a small percentage of mitochondria in archived sec-
tions of NB tumours and in sections published earlier.
Morphologic analysis of mitochondria in NB thus far
received little attention. The true significance of the
observed mitochondrial morphological changes in NB is
intriguing, but does not appear to be related to the muta-
tions we have found.
Conclusions
In contrast to previous findings in PGL and PC, this study
excludes a classical two hit Knudson model for SDHD
involvement in NB. However, the finding of, albeit rare,
bona fide mutations and reduced expression of SDHD in
NB with 11q allelic loss hints at a possible haplo-insuffi-
cient contribution to tumour development. A better
understanding of the different functions of SDHD, in par-
ticular its possible contribution to energy independent
apoptosis involving the release of cytochrome c and pro-
caspases, will allow further functional assays to asses how
this gene contributes to tumour development in general,
and the high stage NB phenotype in particular [59,60].
Mitochondrial ultrastructure shows heterogeneity between cell lines (same fin l magnification for th  4 images, marker = 0.5 µm)Figur  3
Mitochondrial ultrastructure shows heterogeneity between 
cell lines (same final magnification for the 4 images, marker = 
0.5 µm): (A) NB cell line N206: dilated crista spaces in small 
mitochondria with a dense matrix; (B) NB cell line NMB: 
small mitochondria with narrow cristae and light matrix, so-
called orthodox configuration, (C) NB cell line SJNB-8: unu-
sually large mitochondria in orthodox configuration (narrow 
cristae), some areas in the matrix are cleared and lack cris-
tae; (D) NB cell line LA-N-2: very large mitochondria with 
dilated cristae and dense matrix.Page 12 of 15
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BMC Cancer 2004, 4:55 http://www.biomedcentral.com/1471-2407/4/55Evidence for contribution to a cancer phenotype through
haplo-insufficiency has recently been obtained for a
number of loci, including CDKN1B (p27Kip1) [61,62],
TP53 (p53) [63], DMP1 [64], PTEN [65], APC [66] and
NKX3.1 [67]. In mouse models for some of these genes,
loss or mutation of one allele increased tumour suscepti-
bility despite expression of the remaining wild-type allele
[68]. Although the present data on protein and functional
level do not provide consistent evidence for the haplo-
insufficient involvement of SDHD in NB, a bipartite
mechanism as tumour suppressor gene for the SDHD
gene, as described for the APC gene can at present not be
fully excluded. Following this hypothesis, germline muta-
tions in SDHD would predispose to PGL or PC develop-
ment. Rare somatic mutations and more typically loss of
one allele could contribute to the metastasizing NB
tumour phenotype (and possible also other tumour
types), not as an initiating step but rather as later event in
tumour development. However, further evidence is
needed to support the haplo-insufficient involvement of
SDHD in cancer. Ultimately, knockout mice for the SDHD
gene leading to haplo-insufficiency for SDHD in
neuroblast progenitor cells, would be the appropriate test
to evaluate this hypothesis.
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